TrialInternational journal of cancer2011

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

S Tariq Mahmood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.